A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
Status:
Recruiting
Trial end date:
2024-06-06
Target enrollment:
Participant gender:
Summary
The main aim of this study is to evaluate the safety of lanadelumab in Chinese participants
with HAE.
Participants will be treated with a subcutaneous injection of lanadelumab every two weeks for
26 weeks. During the study, each participant will make 16 visits to study clinics.